G Protein–Coupled Receptors Targeting Insulin Resistance, Obesity, and Type 2 Diabetes Mellitus

Cites (365)

Items 201–365 of 365

1. Liraglutide for Type 2 diabetes and obesity: a 2015 update
   Eva Winning Iepsen, Signe S. Torekov, Jens Juul Holst · 2015 · Expert Review of Cardiovascular Therapy
2. GPR40 agonists for the treatment of type 2 diabetes: life after ‘TAKing’ a hit
   Arturo D. Mancini, Vincent Poitout · 2015 · Diabetes Obesity and Metabolism
3. Expression of β3‐adrenoceptor mRNA in rat tissues
   Bronwyn A. Evans, Maria Papaioannou, Vivien R. Bonazzi · 1996 · British Journal of Pharmacology
4. VIP and PACAP: recent insights into their functions/roles in physiology and disease from molecular and genetic studies
   Terry W. Moody, Tetsuhide Ito, Nuramy Osefo · 2011 · Current Opinion in Endocrinology Diabetes and Obesity
5. Common type 2 diabetes risk variant in MTNR1B worsens the deleterious effect of melatonin on glucose tolerance in humans
   Garaulet, Marta, Gómez-Abellán, Purificación, Rubio-Sastre, Patricia, Madrid, Juan A., Saxena, Richa, Scheer, Frank A.J.L. · 2015 · Metabolism
6. Glia: silent partners in energy homeostasis and obesity pathogenesis
   John D. Douglass, Mauricio D. Dorfman, Joshua P. Thaler · 2016 · Diabetologia
7. Peripherally restricted CB1 receptor blockers
   Robert J. Chorvat · 2013 · Bioorganic & Medicinal Chemistry Letters
8. Regulation of Energy Homeostasis by GPR41
   Daisuke Inoue, Gozoh Tsujimoto, Ikuo Kimura · 2014 · Frontiers in Endocrinology
9. Impact of Common Diabetes Risk Variant in MTNR1B on Sleep, Circadian, and Melatonin Physiology
   Jacqueline M. Lane, Anne‐Marie Chang, Andrew Bjonnes, Daniel Aeschbach, Clare Anderson, Brian E. Cade, Sean W. Cain, Charles Andrew Czeisler, Sina A. Gharib, Joshua J. Gooley et al. · 2016 · Diabetes
10. The discovery of drugs for obesity, the metabolic effects of leptin and variable receptor pharmacology: perspectives from β3-adrenoceptor agonists
    Arch, Jonathan R. S. · 2008 · Naunyn-Schmiedeberg's Archives of Pharmacology
11. Role of MCP-1 on inflammatory processes and metabolic dysfunction following high-fat feedings in the FVB/N strain
    Taryn L. Cranford, Reilly T. Enos, Kandy T. Velázquez, Jamie L. McClellan, John M. Davis, Udai Pratap Singh, Mitzi Nagarkatti, Prakash S. Nagarkatti, Cory M. Robinson, E. Angela Murphy · 2015 · International Journal of Obesity
12. The Mammalian Pineal as a Neuroendocrine Transducer
    Richard Jay Wurtman, Fernando Antón‐Tay · 1969 · Elsevier eBooks
13. Benefits and Harms of Once-Weekly Glucagon-like Peptide-1 Receptor Agonist Treatments
    Francesco Zaccardi, Zin Zin Htike, David R. Webb, Kamlesh Khunti, Melanie Jane Davies · 2015 · Annals of Internal Medicine
14. Perspectives in GLP-1 Research: New Targets, New Receptors
    Giulia Cantini, Edoardo Mannucci, Michaela Luconi · 2016 · Trends in Endocrinology and Metabolism
15. Deorphanization of GPR109B as a Receptor for the β-Oxidation Intermediate 3-OH-octanoic Acid and Its Role in the Regulation of Lipolysis
    Kashan Ahmed, Sorin Tunaru, Claus‐Dieter Langhans, Julien Hanson, Christoph W. Michalski, Stefan Kölker, Patricia M. Jones, Jürgen G. Okun, Stefan Offermanns · 2009 · Journal of Biological Chemistry
16. Distribution of glucagon receptors on hormone-specific endocrine cells of rat pancreatic islets
    Timothy J. Kieffer, R. Scott Heller, Cecilia G. Unson, Gordon C. Weir, Joel Francis Habener · 1996 · Endocrinology
17. Inflammation Improves Glucose Homeostasis through IKKβ-XBP1s Interaction
    Junli Liu, Dorina Ibi, Koji Taniguchi, Jaemin Lee, Hilde Herrema, Bedia Akosman, Patrick Mucka, Mario Andrés Salazar Hernández, Muhemmet Fatih Uyar, Sang Won Park et al. · 2016 · Cell
18. Inflammatory changes in adipose tissue enhance expression of GPR84, a medium‐chain fatty acid receptor
    Hiroshi Nagasaki, Takaaki Kondo, Masahiro Fuchigami, Hiroyuki Hashimoto, Yoshihisa Sugimura, Nobuaki Ozaki, Hiroshi Arima, Akira Ota, Yutaka Oiso, Yoji Hamada · 2012 · FEBS Letters
19. Quantification of Gi-Mediated Inhibition of Adenylyl Cyclase Activity Reveals That UDP Is a Potent Agonist of the Human P2Y14 Receptor
    Rhonda L. Carter, Ingrid Fricks, Matthew O. Barrett · 2009 · Molecular Pharmacology
20. CCR2 antagonist CCX140-B provides renal and glycemic benefits in diabetic transgenic human CCR2 knockin mice
    Timothy Sullivan, Zhenhua Miao, Daniel J. Dairaghi, Antoni Krasinski, Yu Wang, Bin N. Zhao, Trageen Baumgart, Linda S. Ertl, Andrew M. K. Pennell, Lisa Seitz et al. · 2013 · American Journal of Physiology-Renal Physiology
21. Antidiabetogenic Action of Cholecystokinin-8 in Type 2 Diabetes
    Bo Åhrén, Jens Juul Holst, Suad Efendić · 2000 · The Journal of Clinical Endocrinology & Metabolism
22. Fasiglifam (TAK-875) Inhibits Hepatobiliary Transporters: A Possible Factor Contributing to Fasiglifam-Induced Liver Injury
    Xiuli Li, Kan Zhong, Zitao Guo, Dafang Zhong, Xiaoyan Chen · 2015 · Drug Metabolism and Disposition
23. A potentiator of orthosteric ligand activity at GLP-1R acts via covalent modification
    Nolte, Whitney M, Fortin, Jean-Philippe, Stevens, Benjamin D, Aspnes, Gary E, Griffith, David A, Hoth, Lise R, Ruggeri, Roger B, Mathiowetz, Alan M, Limberakis, Chris, Hepworth, David et al. · 2014 · Nature Chemical Biology
24. Peripheral Monocytes of Obese Women Display Increased Chemokine Receptor Expression and Migration Capacity
    Patricia Krinninger, Regina E. Ensenauer, Kerstin Ehlers, Kathrin Rauh, J. Stoll, Susanne Krauss‐Etschmann, Hans Hauner, Helmut Laumen · 2014 · The Journal of Clinical Endocrinology & Metabolism
25. GPR105 Ablation Prevents Inflammation and Improves Insulin Sensitivity in Mice with Diet-Induced Obesity
    Jianfeng Xu, Hidetaka Morinaga, Dayoung Oh, Pingping Li, Ai Chen, Saswata Talukdar, Eduardo Rodolfo Lazarowski, Jerrold M. Olefsky, Jane J. Kim · 2012 · The Journal of Immunology
26. Evaluation of the insulin releasing and antihyperglycaemic activities of GPR55 lipid agonists using clonal beta‐cells, isolated pancreatic islets and mice
    Aine M. McKillop, Brian Michael Moran, Yasser H.A. Abdel‐Wahab, Peter R. Flatt · 2013 · British Journal of Pharmacology
27. GPR119 Regulates Murine Glucose Homeostasis Through Incretin Receptor-Dependent and Independent Mechanisms
    Grace B. Flock, Dianne P. Holland, Yutaka Seino, Daniel J. Drucker · 2010 · Endocrinology
28. Activation of G protein-coupled receptor 30 modulates hormone secretion and counteracts cytokine-induced apoptosis in pancreatic islets of female mice
    Alexander Balhuizen, Rajesh Kumar, Stefan Amisten, Ingmar Lundquist, Albert A. Salehi · 2010 · Molecular and Cellular Endocrinology
29. Activation of melatonin signaling promotes β-cell survival and function
    Costes, Safia, Boss, Marti, Thomas, Anthony P., Matveyenko, Aleksey V. · 2015 · Molecular Endocrinology
30. Sequence-structure based phylogeny of GPCR Class A Rhodopsin receptors
    Kavita Kumari Kakarala, Kaiser Jamil · 2014 · Molecular Phylogenetics and Evolution
31. Small Molecule Drug Discovery at the Glucagon-Like Peptide-1 Receptor
    Francis S. Willard, Ana Belen Bueno, Kyle W. Sloop · 2012 · Experimental Diabetes Research
32. GPR35 as a Novel Therapeutic Target
    Alex MacKenzie, J. E. Lappin, Debra L. Taylor, Stuart A. Nicklin, Graeme Milligan · 2011 · Frontiers in Endocrinology
33. GPRC6A regulates prostate cancer progression
    Min Pi, L. Darryl Quarles · 2011 · The Prostate
34. Insulinotropic and Antidiabetic Effects of 17β-Estradiol and the GPR30 Agonist G-1 on Human Pancreatic Islets
    Rajesh Kumar, Alexander Balhuizen, Stefan Amisten, Ingmar Lundquist, Albert A. Salehi · 2011 · Endocrinology
35. A Novel Allosteric Activator of Free Fatty Acid 2 Receptor Displays Unique Gi-functional Bias
    Daniele Bolognini, Daryl Hodge, Karolina A. Nilsson, Annika Petersson, Iona Donnelly, Eugenia Sergeev, Gabriele Maria König, Evi Kostenis, Mariola Kurowska‐Stolarska, Ashley M. Miller et al. · 2016 · Journal of Biological Chemistry
36. Extracellular Loop 2 of the Free Fatty Acid Receptor 2 Mediates Allosterism of a Phenylacetamide Ago-Allosteric Modulator
    Nicola J. Smith, Richard John Ward, Leigh A. Stoddart, Brian D. Hudson, Evi Kostenis, Trond Ulven, Joanne C. Morris, Christian Tränkle, Irina G. Tikhonova, David R. Adams et al. · 2011 · Molecular Pharmacology
37. AMP-Activated Protein Kinase Activation by Adrenoceptors in L6 Skeletal Muscle Cells
    Dana S. Hutchinson, Tore Bengtsson · 2006 · Diabetes
38. Multiple signalling pathways involved in β2‐adrenoceptor‐mediated glucose uptake in rat skeletal muscle cells
    Julia Nevzorova, Bronwyn A. Evans, Tore Bengtsson, Roger J. Summers · 2006 · British Journal of Pharmacology
39. GLP1 and cancer: friend or foe?
    Roman Vangoitsenhoven, Chantal Mathieu, Bart Van der Schueren · 2012 · Endocrine Related Cancer
40. GPRC5B Activates Obesity-Associated Inflammatory Signaling in Adipocytes
    Yeon‐Jeong Kim, Takamitsu Sano, Takuji Nabetani, Yoshimi Asano, Yoshio Hirabayashi · 2012 · Science Signaling
41. The PGE2 EP3 Receptor Regulates Diet-Induced Adiposity in Male Mice
    Ryan P. Ceddia, Daekee Lee, Matthew F. Maulis, Lindsey Carboneau, David W. Threadgill, Greg Poffenberger, Ginger L. Milne, Kelli Lynn Boyd, Alvin C. Powers, Owen P. McGuinness et al. · 2015 · Endocrinology
42. GPRC6A Mediates the Effects of l-Arginine on Insulin Secretion in Mouse Pancreatic Islets
    Min Pi, Yunpeng Wu, Nataliya I. Lenchik, Ivan Gerling, L. Darryl Quarles · 2012 · Endocrinology
43. GLP‐1R and amylin agonism in metabolic disease: complementary mechanisms and future opportunities
    Roth, Jonathan D, Erickson, Mary R, Chen, Steve, Parkes, David G · 2012 · British Journal of Pharmacology
44. No evidence for a bone phenotype in GPRC6A knockout mice under normal physiological conditions
    Petrine Wellendorph, Lars Dan Johansen, Anders A. Jensen, Emilio Casanova, Martin Gassmann, Pierre Deprez, Philippe Clément-Lacroix, Bernhard Bettler, Hans Bräuner‐Osborne · 2008 · Journal of Molecular Endocrinology
45. Macrophage-specific de Novo Synthesis of Ceramide Is Dispensable for Inflammasome-driven Inflammation and Insulin Resistance in Obesity
    Christina D. Camell, Kim Nguyen, Michael J. Jurczak, Brooke E. Christian, Gerald I. Shulman, Gerald S. Shadel, Vishwa Deep Dixit · 2015 · Journal of Biological Chemistry
46. Characterization of the β‐adrenoceptor subtype involved in mediation of glucose transport in L6 cells
    Julia Nevzorova, Tore Bengtsson, Bronwyn A. Evans, Roger J. Summers · 2002 · British Journal of Pharmacology
47. Quantification of Functional Selectivity at the Human α1A-Adrenoceptor
    Bronwyn A. Evans, Natalie M. Broxton, Jon Merlin, Masaaki Sato, Dana S. Hutchinson, Arthur Christopoulos, Roger J. Summers · 2010 · Molecular Pharmacology
48. Agonism and allosterism: the pharmacology of the free fatty acid receptors FFA2 and FFA3
    Graeme Milligan, Leigh A. Stoddart, Nicola J. Smith · 2009 · British Journal of Pharmacology
49. Deletion of G-protein-coupled receptor 55 promotes obesity by reducing physical activity
    Adelina G. Meadows, J. H. Lee, Chia‐Shan Wu, Qiong Wei, Geetali Pradhan, Michael Yafi, H-C Lu, Yuxiang Sun · 2015 · International Journal of Obesity
50. Dorothy Hodgkin Lecture 2008 Gastric inhibitory polypeptide (GIP) revisited: a new therapeutic target for obesity–diabetes?
    Flatt, P. R. · 2008 · Diabetic Medicine
51. Multiple Binding Sites for Small-Molecule Antagonists at the CC Chemokine Receptor 2
    Annelien J.M. Zweemer, Indira Nederpelt, Hilde Vrieling et al. · 2013 · Molecular Pharmacology
52. G protein–coupled receptor 21 deletion improves insulin sensitivity in diet-induced obese mice
    Olivia Osborn, Da Young Oh, Joanne McNelis, Manuel Sánchez-Alavez, Saswata Talukdar, Min M. Lu, Pingping Li, Lucinda Thiede, Hidetaka Morinaga, Jane J. Kim et al. · 2012 · Journal of Clinical Investigation
53. Alternative splicing generates two isoforms of the β3‐adrenoceptor which are differentially expressed in mouse tissues
    Bronwyn A. Evans, Maria Papaioannou, Stephanie Hamilton · 1999 · British Journal of Pharmacology
54. Delineation of the GPRC6A Receptor Signaling Pathways Using a Mammalian Cell Line Stably Expressing the Receptor
    Stine Engesgaard Jacobsen, Lenea Nørskov-Lauritsen, Alex Rojas Bie Thomsen, Sanela Smajilovic, Petrine Wellendorph, Niklas Larsson, Anders Lehmann, Vikram Kjøller Bhatia, Hans Bräuner‐Osborne · 2013 · Journal of Pharmacology and Experimental Therapeutics
55. An siRNA Screen in Pancreatic Beta Cells Reveals a Role for Gpr27 in Insulin Production
    Gregory Ku, Zachary Pappalardo, Chun Chieh Luo, Michael S. German, Michael T. McManus · 2012 · PLoS Genetics
56. Gut Hormone Pharmacology of a Novel GPR119 Agonist (GSK1292263), Metformin, and Sitagliptin in Type 2 Diabetes Mellitus: Results from Two Randomized Studies
    Derek J. Nunez, Mark Bush, David A. Collins, Susan L. McMullen, Dawn Gillmor, Glen Apseloff, George J. Atiee, Leonor Corsino, Linda Morrow, Paul L. Feldman · 2014 · PLoS ONE
57. The Discovery, Preclinical, and Early Clinical Development of Potent and Selective GPR40 Agonists for the Treatment of Type 2 Diabetes Mellitus (LY2881835, LY2922083, and LY2922470)
    Chafiq Hamdouchi, Steven D. Kahl, Anjana Patel Lewis, Guemalli R. Cardona, Richard W. Zink, Keyue Chen, Thomas E. Eessalu, JAMES V. FICORILLI, Marialuisa C. Marcelo, Keith A. Otto et al. · 2016 · Journal of Medicinal Chemistry
58. GPR84 deficiency reduces microgliosis, but accelerates dendritic degeneration and cognitive decline in a mouse model of Alzheimer’s disease
    Julie Audoy-Rémus, Lusiné Bozoyan, Aline Dumas, Mohammed Filali, Cynthia Lecours, Steve Lacroix, Serge Rivest, Marie‐Ève Tremblay, Luc Vallières · 2015 · Brain Behavior and Immunity
59. Murine GPRC6A Mediates Cellular Responses to L-Amino Acids, but Not Osteocalcin Variants
    Patricia Rueda, Elizabeth A. Harley, Yao Wei Lu, Gregory D. Stewart, Stewart A. Fabb, Natalie A. Diepenhorst, Béatrice Cremers, Marie-Hélène Rouillon, Isabelle Wehrle, Anne Géant et al. · 2016 · PLoS ONE
60. The G Protein-coupled Receptor P2Y14 Influences Insulin Release and Smooth Muscle Function in Mice
    Jaroslawna Meister, Diana Le Duc, Albert Markus Ricken, Ralph Burkhardt, Joachim Thiery, Helga Pfannkuche, Tobias Polte, Johannes Grosse, Torsten Schöneberg, Angela Schulz · 2014 · Journal of Biological Chemistry
61. Relationship Between Insulin Resistance and β-Cell Dysfunction in Subphenotypes of Prediabetes and Type 2 Diabetes
    Kristine Færch, Nanna Borup Johansen, Daniel R. Witte, Torsten Lauritzen, Marit E. Jørgensen, Dorte Vistisen · 2014 · The Journal of Clinical Endocrinology & Metabolism
62. Orthologue selectivity and ligand bias: translating the pharmacology of GPR35
    Graeme Milligan · 2011 · Trends in Pharmacological Sciences
63. GPR119 expression in normal human tissues and islet cell tumors: evidence for its islet-gastrointestinal distribution, expression in pancreatic beta and alpha cells, and involvement in islet function
    Shinji Odori, Kiminori Hosoda, Tsutomu Tomita, Junji Fujikura, Toru Kusakabe, Yoshiya Kawaguchi, Ryuichiro Doi, Kyoichi Takaori, Ken Ebihara, Yoshiharu Sakai et al. · 2012 · Metabolism
64. Identification of Signal Transduction Pathways Used by Orphan G Protein-Coupled Receptors
    Janine N. Bresnick, Heather A. Skynner, Kerry L. Chapman · 2003 · Assay and Drug Development Technologies
65. Silencing CCR2 in Macrophages Alleviates Adipose Tissue Inflammation and the Associated Metabolic Syndrome in Dietary Obese Mice
    Jong-Kil Kim, Kunho Chung, Changseon Choi, Jagadish Beloor, Irfan Ullah, Nahyeon Kim, Kuen Yong Lee, Sang‐Kyung Lee, Priti Kumar · 2016 · Molecular Therapy — Nucleic Acids
66. α2-Adrenoceptor Blockade Does Not Enhance Glucose-Induced Insulin Release in Normal Subjects or Patients With Noninsulin-Dependent Diabetes*
    Claes‐Göran Östenson, Jan Pigon, John C. Doxey, Suad Efendić · 1988 · The Journal of Clinical Endocrinology & Metabolism
67. Different Effects of the Different Natural CC Chemokine Receptor 2b Ligands on β-Arrestin Recruitment, Gαi Signaling, and Receptor Internalization
    Yamina A. Berchiche, Stéphanie Gravel, Marie-Eve Pelletier · 2010 · Molecular Pharmacology
68. Experimental evidence for the use of CCR2 antagonists in the treatment of type 2 diabetes
    Timothy J. Sullivan, Zhenhua Miao, Bin N. Zhao, Linda S. Ertl, Yu Wang, Antoni Krasinski, Matthew J. Walters, Jay P. Powers, Daniel J. Dairaghi, Trageen Baumgart et al. · 2013 · Metabolism
69. The l-α-amino acid receptor GPRC6A is expressed in the islets of Langerhans but is not involved in l-arginine-induced insulin release
    Sanela Smajilovic, Christoffer Clemmensen, Lars Dan Johansen, Petrine Wellendorph, Jens Juul Holst, Peter Thams, Egbuna Ogo, Hans Bräuner‐Osborne · 2012 · Amino Acids
70. UDP Is a Competitive Antagonist at the Human P2Y14 Receptor
    Ingrid Fricks, Savitri Maddileti, Rhonda L. Carter · 2008 · Journal of Pharmacology and Experimental Therapeutics
71. Neuroprotective Effects of the Glucagon-Like Peptide-1 Analog Exenatide After Out-of-Hospital Cardiac Arrest
    Sebastian C. Wiberg, Christian Hassager, Henrik Schmidt et al. · 2016 · Circulation
72. An Oral Selective Alpha-1A Adrenergic Receptor Agonist Prevents Doxorubicin Cardiotoxicity
    Ju Youn Beak, Wei Huang, Joel S. Parker, Sean T. Hicks, Cam Patterson, Paul C. Simpson, Anqi Ma, Jian Jun Jin, Brian C. Jensen · 2017 · JACC Basic to Translational Science
73. Metabolic Roles of the M3Muscarinic Acetylcholine Receptor Studied with M3Receptor Mutant Mice: A Review
    Dinesh Gautam, Jongrye Jeon, Jian Hua Li, Sung‐Jun Han, Fadi F. Hamdan, Yinghong Cui, Huiyan Lü, Chu‐Xia Deng, Oksana Gavrilova, Jürgen Wess · 2008 · Journal of Receptors and Signal Transduction
74. GPR119: a promising target for nonalcoholic fatty liver disease
    Jin Won Yang, Hyo Seon Kim, Ji Hye Im, Ji Won Kim, Dae Won Jun, Sung‐Chul Lim, Kyeong Lee, Jong Min Choi, Sang Kyum Kim, Keon Wook Kang · 2015 · The FASEB Journal
75. GPR30 regulates diet-induced adiposity in female mice and adipogenesis in vitro
    Aihua Wang, Jing Luo, William Moore, Hana Alkhalidy, Ling Wu, Jinhua Zhang, Zhen Cheng Wei, Yao Wang, Deborah J. Clegg, Bin Xu et al. · 2016 · Scientific Reports
76. β3-Adrenergic Receptor Stimulation Induces E-Selectin-mediated Adipose Tissue Inflammation
    Rachel J. Roth Flach, Anouch Matevossian, Thomas E. Akie, Kimberly A. Negrin, M. Paul, Michael Czech · 2012 · Journal of Biological Chemistry
77. GPR55: From orphan to metabolic regulator?
    Bo Liu, Shuang Song, Peter M. Jones, Shanta Jean Persaud · 2014 · Pharmacology & Therapeutics
78. The direct effects of catecholamines on hepatic glucose production occur via α1- and β2-receptors in the dog
    Chang An Chu, Dana K. Sindelar, Kayano Igawa · 2000 · American Journal of Physiology-Endocrinology and Metabolism
79. Targeting Inflammation Using Salsalate in Patients With Type 2 Diabetes: Effects on Flow-Mediated Dilation (TINSAL-FMD)
    Allison B. Goldfine, J. Stewart Buck, Cyrus V Desouza, Vivian Andrew Fonseca, Yii-Der Ida Chen, Steven E. Shoelson, Kathleen A. Jablonski, Mark A. Creager, for the TINSAL-FMD (Targeting Inflammation Using Salsalate in Type 2 Diabetes–Flow-Mediated Dilation) Ancillary Study Team · 2013 · Diabetes Care
80. Effect of GPR84 deletion on obesity and diabetes development in mice fed long chain or medium chain fatty acid rich diets
    Eugene Du Toit, Liam Browne, Helen F. Irving‐Rodgers, Helen Maureen Massa, Nicolette Fozzard, Michael P. Jennings, Ian R. A. Peak · 2017 · European Journal of Nutrition
81. Comparison of exendin-4 on beta-cell replication in mouse and human islet grafts
    Lei Tian, Jie Gao, G. Weng, Huimin Yi, Bole Tian, Timothy D. O’Brien, Zhiguang Guo · 2011 · Transplant International
82. Osteocalcin and Sex Hormone Binding Globulin Compete on a Specific Binding Site of GPRC6A
    Luca De Toni, Diego Guidolin, Vincenzo De Filippis, Simone Tescari, Giacomo Strapazzon, Maria Santa Rocca, Alberto Ferlin, Mario Plebani, Carlo Foresta · 2016 · Endocrinology
83. GPR119 agonists: a promising approach for T2DM treatment? A SWOT analysis of GPR119
    Sang-Uk Kang · 2013 · Drug Discovery Today
84. Control of hepatic gluconeogenesis: Role of fatty acid oxidation
    Consuelo González‐Manchón, Matilde S. Ayuso, Roberto Parrilla · 1989 · Archives of Biochemistry and Biophysics
85. Addressing Unmet Medical Needs in Type 2 Diabetes: A Narrative Review of Drugs under Development
    Friedrich Mittermayer, Erica J. Caveney, Cláudia de Fátima OLIVEIRA, Loukas Gourgiotis, Mala Puri, Li-Jung Tai, J. Rick Turner · 2015 · Current Diabetes Reviews
86. Safety and tolerability of β3-adrenoceptor agonists in the treatment of overactive bladder syndrome – insight from transcriptosome and experimental studies
    Martin Christian Michel, Stavros Gravas · 2016 · Expert Opinion on Drug Safety
87. The Effects of the β3-Adrenoceptor Agonist BRL 35135 on UCP Isoform mRNA Expression
    Valur Emilsson, Roger J. Summers, Stephanie Hamilton, Yong-Ling Liu, Michael A. Cawthorne · 1998 · Biochemical and Biophysical Research Communications
88. Aberrant Accumulation of Undifferentiated Myeloid Cells in the Adipose Tissue of CCR2-Deficient Mice Delays Improvements in Insulin Sensitivity
    Dario A. Gutierrez, Arion J. Kennedy, Jeb S. Orr, Emily K. Anderson‐Baucum, Corey D. Webb, William K. Gerrald, Alyssa H. Hasty · 2011 · Diabetes
89. The G protein-coupled receptor GPRC5B contributes to neurogenesis in the developing mouse neocortex
    Kurabayashi, Nobuhiro, Nguyen, Minh Dang, Sanada, Kamon · 2013 · Development
90. Endogenous Ligand for GPR120, Docosahexaenoic Acid, Exerts Benign Metabolic Effects on the Skeletal Muscles via AMP-activated Protein Kinase Pathway
    Nami Kim, Jung Ok Lee, Hye Jeong Lee, Hyung Ip Kim, Joong Kwan Kim, Soo Kyung Lee, Soo Kyung Lee, Su Jin Kim, Sun Hwa Park, Hyeon Soo Kim · 2015 · Journal of Biological Chemistry
91. Enriching Islet Phospholipids With Eicosapentaenoic Acid Reduces Prostaglandin E2 Signaling and Enhances Diabetic β-Cell Function
    Joshua Charles Neuman, Michael D. Schaid, Allison L. Brill, Rachel J. Fenske, Carly R. Kibbe, Danielle A. Fontaine, Sophia M. Sdao, Harpreet K. Brar, Kelsey M. Connors, Haley N. Wienkes et al. · 2017 · Diabetes
92. Potent and Orally Bioavailable GPR142 Agonists as Novel Insulin Secretagogues for the Treatment of Type 2 Diabetes
    Narihiro Toda, Xiaolin Hao, Yasuyuki Ogawa et al. · 2013 · ACS Medicinal Chemistry Letters
93. G-protein-coupled receptor GPR21 knockout mice display improved glucose tolerance and increased insulin response
    Jonitha Gardner, Sue Wu, Lei Ling · 2011 · Biochemical and Biophysical Research Communications
94. An mRNA atlas of G protein-coupled receptor expression during primary human monocyte/macrophage differentiation and lipopolysaccharide-mediated activation identifies targetable candidate regulators of inflammation
    Daniel M. Hohenhaus, Kolja Schaale, Kim‐Anh Lê Cao, Vernon Seow, Abishek Iyer, David P. Fairlie, Matthew J. Sweet · 2013 · Immunobiology
95. G Protein-coupled Receptor 40 (GPR40) and Peroxisome Proliferator-activated Receptor γ (PPARγ)
    Shuibang Wang, Keytam S. Awad, Jason M. Elinoff, Edward J. Dougherty, Gabriela A. Ferreyra, Jennifer Y. Wang, Rongman Cai, Junfeng Sun, Anetta Ptasinska, Robert L. Danner · 2015 · Journal of Biological Chemistry
96. In Vivo Response to α1‐Adrenoreceptor Stimulation in Human White Adipose Tissue
    Michael Boschmann, Götz Krupp, Friedrich Cameron Luft · 2002 · Obesity Research
97. Chemogenomic Discovery of Allosteric Antagonists at the GPRC6A Receptor
    David E.I. Gloriam, Petrine Wellendorph, Lars Dan Johansen, Alex Rojas Bie Thomsen, Karina Phonekeo, Daniel Sejer Pedersen, Hans Bräuner‐Osborne · 2011 · Chemistry & Biology
98. Minireview: Signal Bias, Allosterism, and Polymorphic Variation at the GLP-1R: Implications for Drug Discovery
    Cassandra Koole, Emilia E. Savage, Arthur Christopoulos, Laurence J. Miller, Patrick Michael Sexton, Denise L. Wootten · 2013 · Molecular Endocrinology
99. Effects of CB1 antagonist on the control of metabolic functions in obese type 2 diabetic patients
    Max Lafontan, P.V. Piazza, Jean R Girard · 2007 · Diabetes & Metabolism
100. Identification of Glial Activation Markers by Comparison of Transcriptome Changes between Astrocytes and Microglia following Innate Immune Stimulation
     Silvia Madeddu, Tyson A. Woods, Piyali Mukherjee, Dan E. Sturdevant, Niranjan Babu Butchi, Karin E. Peterson · 2015 · PLoS ONE
101. GPRC5B a putative glutamate-receptor candidate is negative modulator of insulin secretion
     Arvind Soni, Stefan Amisten, Patrik Rorsman, Albert A. Salehi · 2013 · Biochemical and Biophysical Research Communications
102. A potential role for GPR55 in the regulation of energy homeostasis
     Anna C Simcocks, Lannie O’Keefe, Kayte A. Jenkin, Michael L. Mathai, Deanne Helena Hryciw, Andrew J. McAinch · 2013 · Drug Discovery Today
103. FFA4 receptor (GPR120): A hot target for the development of anti-diabetic therapies
     Hongda Liu, Wenbo Wang, Zhigang Xu, Changhong Liu, Dongfang He, Lv-Pei Du, Minyong Li, Xiao Yu, Jin‐Peng Sun · 2015 · European Journal of Pharmacology
104. Endogenous GLP-1 as a key self-defense molecule against lipotoxicity in pancreatic islets
     HUANG, CHENGHU, YUAN, LI, CAO, SHUYI · 2015 · International Journal of Molecular Medicine
105. GPR43 – A Prototypic Metabolite Sensor Linking Metabolic and Inflammatory Diseases
     Craig I. McKenzie, Charles Reay Mackay, Laurence Macia · 2015 · Trends in Endocrinology and Metabolism
106. Relationship between β-2 adrenoceptor gene haplotypes and adipocyte lipolysis in women
     Per Olof Eriksson, Ingrid A. Dahlman, Mikael Rydén, Johan Hoffstedt, Peter Arner · 2003 · International Journal of Obesity
107. Treating diabetic nephropathy—still an unresolved issue
     Mark Emmanuel Cooper · 2012 · Nature Reviews Endocrinology
108. Association of Antidiabetic Medications Targeting the Glucagon-Like Peptide 1 Pathway and Heart Failure Events in Patients With Diabetes
     Mauricio Velez, Edward L. Peterson, Karen E. Wells, Tanmay V. Swadia, Hani N. Sabbah, L. Keoki Williams, David E. Lanfear · 2014 · Journal of Cardiac Failure
109. Review of current and emerging therapies in type 2 diabetes mellitus.
     Nissa Mazzola · 2012 · PubMed
110. Molecular matchmaking between the popular weight-loss herb Hoodia gordonii and GPR119, a potential drug target for metabolic disorder
     Shuyong Zhang, Yuyong Ma, Jing Li · 2014 · Proceedings of the National Academy of Sciences
111. Future of GPR109A agonists in the treatment of dyslipidaemia
     Desiree Wanders, Robert L. Judd · 2011 · Diabetes Obesity and Metabolism
112. Increased susceptibility to diet-induced obesity in GPRC6A receptor knockout mice
     Christoffer Clemmensen, Sanela Smajilovic, Andreas Nygaard Madsen, Anders Bue Klein, Birgitte Holst, Hans Bräuner‐Osborne · 2013 · Journal of Endocrinology
113. Deficiency in the metabolite receptor SUCNR1 (GPR91) leads to outer retinal lesions
     Sandra Favret, François Binet, Eric Lapalme, Dominique Leboeuf, Jose Carbadillo, Tina Rubic, Émilie Picard, Gaëlle Mawambo, Nicolas Tetreault, Jean‐Sébastien Joyal et al. · 2013 · Aging
114. β 2 ‐Adrenoceptors increase translocation of GLUT4 via GPCR kinase sites in the receptor C‐terminal tail
     Nodi Dehvari, Dana S. Hutchinson, Julia Nevzorova, Olof Stefan Dallner, Masaaki Sato, Martina Kočan, Jon Merlin, Bronwyn A. Evans, Roger J. Summers, Tore Bengtsson · 2011 · British Journal of Pharmacology
115. Anti-hyperglycaemic action of BRL 26830, a novel β-adrenoceptor agonist, in mice and rats
     Matthew V. Sennitt, Jonathan R.S. Arch, Alison L. Levy, Diane L. Simson, Stephen A. Smith, Michael Anthony Cawthorne · 1985 · Biochemical Pharmacology
116. Season-dependent associations of circadian rhythm-regulating loci (CRY1, CRY2 and MTNR1B) and glucose homeostasis: the GLACIER Study
     Frida Renström, Robert Wilhelm Koivula, Tibor V. Varga, Göran Hallmans, Hindrik Mulder, José C. Florez, Frank B. Hu, Paul W. Franks · 2015 · Diabetologia
117. Discovery and optimization of a novel series of GPR142 agonists for the treatment of type 2 diabetes mellitus
     Mike E. Lizarzaburu, Simon Turcotte, Xiaohui Du, Jason Duquette, Angela Fu, Jonathan B. Houze, Leping Li, Jinqian Liu, Michiko Murakoshi, Kozo Oda et al. · 2012 · Bioorganic & Medicinal Chemistry Letters
118. GPR84 deficiency reduces microgliosis, but accelerates dendritic degeneration and cognitive decline in a mouse model of Alzheimer's disease
     Lusiné Bozoyan, Julie Audoy-Rémus, Aline Dumas, Mohammed Filali, Steve Lacroix, Serge Rivest, Marie‐Ève Tremblay, Luc Vallières · 2014 · Journal of Neuroimmunology
119. GSK256073 , a selective agonist of G‐protein coupled receptor 109A (GPR109A) reduces serum glucose in subjects with type 2 diabetes mellitus
     Robert L. Dobbins, Shawn Patrick Shearn, RL Byerly, F. F. Gao, Kelly M. Mahar, A. Napolitano, Gaëlle Nachbaur, Anne‐Charlotte Le Monnier de Gouville · 2013 · Diabetes Obesity and Metabolism
120. Clenbuterol prevents epinephrine from antagonizing insulin-stimulated muscle glucose uptake
     Desmond G. Hunt, Zhenping Ding, John L. Ivy · 2002 · Journal of Applied Physiology
121. GPR142 Agonists Stimulate Glucose-Dependent Insulin Secretion via Gq-Dependent Signaling
     Jingru Wang, Juan J. Carrillo, Hua V. Lin · 2016 · PLoS ONE
122. Reduced Food Intake and Body Weight in Mice Deficient for the G Protein-Coupled Receptor GPR82
     Kathrin M. Engel, Kristin Schröck, Daniel Teupser, Lesca Miriam Holdt, Anke Tönjes, Matthias Kern, Kerstin Dietrich, Peter Louis Kovacs, Ute Krügel, Holger A. Scheidt et al. · 2011 · PLoS ONE
123. Global analysis of glycoproteins identifies markers of endotoxin tolerant monocytes and GPR84 as a modulator of TNFα expression
     Mario M. Müller, Roland Lehmann, Tilman E. Klassert, Stella Reifenstein, Theresia Conrad, Christoph Moore, Anna Michele Kühn, Andrea Behnert, Reinhard Guthke, Dominik Driesch et al. · 2017 · Scientific Reports
124. Ibipinabant attenuates β ‐cell loss in male Zucker diabetic fatty rats independently of its effects on body weight
     Kenneth W. Rohrbach, Michael A. Thomas, Susan Glick, Ellen Fung, V. Wang, L. Watson, P. Gregory, J. Antel, Mary Ann Pelleymounter · 2012 · Diabetes Obesity and Metabolism
125. Sympathetic Regulation of Glucose Uptake by the α1‐Adrenoceptor in Human Obesity
     Marion Flechtner‐Mors, Christopher P. Jenkinson, Andreas Alt · 2004 · Obesity Research
126. Functional Analysis of Free Fatty Acid Receptor GPR120 in Human Eosinophils: Implications in Metabolic Homeostasis
     Yasunori Konno, Shigeharu Ueki, Masahide Takeda et al. · 2015 · PLoS ONE
127. α1A-Adrenergic receptor prevents cardiac ischemic damage through PKCδ/GLUT1/4-mediated glucose uptake
     Ting Shi, Robert S. Papay, Dianne M. Perez · 2015 · Journal of Receptors and Signal Transduction
128. β-Cell Inactivation of Gpr119 Unmasks Incretin Dependence of GPR119-Mediated Glucoregulation
     Brandon L. Panaro, Grace B. Flock, Jonathan Edward Campbell, Jacqueline Leah Beaudry, Xiemin Cao, Daniel J. Drucker · 2017 · Diabetes
129. The rs2274911 polymorphism in GPRC 6A gene is associated with insulin resistance in normal weight and obese subjects
     Andrea Di Nisio, Maria Santa Rocca, Gian Paolo Fadini, Luca De Toni, Giorgio Marcuzzo, Maria Cristina Marescotti, Marta Sanna, Mario Plebani, Roberto Vettor, Angelo Avogaro et al. · 2016 · Clinical Endocrinology
130. Dulaglutide (Trulicity): The Third Once-Weekly GLP-1 Agonist.
     Lillian L Smith, Juan Mosley, Crystal K. Parke, Jamal Brown, Barris Ls, Linh D. Phan · 2016 · PubMed Central
131. For Better or Worse: FFAR1 and FFAR4 Signaling in Cancer and Diabetes
     Julia M. Houthuijzen · 2016 · Molecular Pharmacology
132. Genetic Variations in the Human G Protein-coupled Receptor Class C, Group 6, Member A (GPRC6A) Control Cell Surface Expression and Function
     Stine Jørgensen, Christian Theil Have, Christina Rye Underwood, Lars Dan Johansen, Petrine Wellendorph, Anette P. Gjesing, Christinna V. Jørgensen, Shi Quan, Gao Rui, Asuka Inoue et al. · 2016 · Journal of Biological Chemistry
133. Effect of an oral α2-adrenergic blocker (MK-912) on pancreatic islet function in non-insulin-dependent diabetes mellitus
     F. J. Ortiz-Alonso, William H. Herman, Barry J. Gertz, Vanessa C. Williams, Marla J. Smith, Jeffrey B. Halter · 1991 · Metabolism
134. Aminopyrazole–Phenylalanine Based GPR142 Agonists: Discovery of Tool Compound and in Vivo Efficacy Studies
     Ming Yu, Mike E. Lizarzaburu, Alykhan S. Motani et al. · 2013 · ACS Medicinal Chemistry Letters
135. Extracellular acidification stimulates GPR68 mediated IL-8 production in human pancreatic β cells
     Vikash Chandra, Angeliki Karamitri, Paul Richards, Françoise Cormier, Cyrille Ramond, Ralf Jockers, Mathieu Armanet, Olivier Albagli, Raphaël Scharfmann · 2016 · Scientific Reports
136. Discovery and characterization of GSK256073, a non-flushing hydroxy-carboxylic acid receptor 2 (HCA2) agonist
     Dennis L. Sprecher, Miles P. Maxwell, Joanne Goodman · 2015 · European Journal of Pharmacology
137. α 2A -Adrenergic Receptors in the Genetics, Pathogenesis, and Treatment of Type 2 Diabetes
     Stephen B. Liggett · 2009 · Science Translational Medicine
138. Cannabinoid-1 receptor antagonists in type-2 diabetes
     André Jacques Scheen · 2007 · Best Practice & Research Clinical Endocrinology & Metabolism
139. Association of the ADRA1A gene and the severity of metabolic abnormalities in patients with schizophrenia
     Chin Cheng, Hsien-Jane Chiu, El‐Wui Loh, Chin-Hong Chan, Tzong-Ming Hwu, Yun‐Ru Liu, Tsuo‐Hung Lan · 2011 · Progress in Neuro-Psychopharmacology and Biological Psychiatry
140. Role of α1A-adrenoceptor in the regulation of glucose uptake into white adipocyte of rats in vitro
     Juei-Tang Cheng, I.-Min Liu, Shi-Ting Yen · 2000 · Autonomic Neuroscience
141. Selective Allosteric Antagonists for the G Protein-Coupled Receptor GPRC6A Based on the 2-Phenylindole Privileged Structure Scaffold
     Henrik Johansson, Michael W. Boesgaard, Lenea Nørskov-Lauritsen, Inna Larsen, Sebastiaan Kuhne, David E.I. Gloriam, Hans Bräuner‐Osborne, Daniel Sejer Pedersen · 2015 · Journal of Medicinal Chemistry
142. Phenylalanine derivatives as GPR142 agonists for the treatment of Type II diabetes
     Xiaohui Du, Yong‐Jae Kim, Sujen Lai et al. · 2012 · Bioorganic & Medicinal Chemistry Letters
143. Biological Characteristics and Agonists of GPR120 (FFAR4) Receptor: The Present Status of Research
     Ang Li, Yue Li, Lüpei Du · 2015 · Future Medicinal Chemistry
144. Regulating the effects of GPR21, a novel target for type 2 diabetes
     Siobhán Leonard, Gemma K. Kinsella, Elisa Benetti, John B. C. Findlay · 2016 · Scientific Reports
145. GSK256073 acutely regulates NEFA levels via HCA2 agonism but does not achieve durable glycaemic control in type 2 diabetes. A randomised trial
     Robert L. Dobbins, RL Byerly, Riley Gaddy, Feng Gao, Kelly M. Mahar, Antonella Napolitano, Phil Ambery, Anne‐Charlotte Le Monnier de Gouville · 2015 · European Journal of Pharmacology
146. Effects of novel beta-adrenoceptor agonists on carbohydrate metabolism: relevance for the treatment of non-insulin-dependent diabetes.
     MA Cawthorne, Michael J. Carroll, A L Levy · 1984 · PubMed
147. Synergistic Effects of a GPR119 Agonist with Metformin on Weight Loss in Diet-Induced Obese Mice
     Kamal A. Albarazanji, Judi A. McNulty, Jane G. Binz, Claudia Generaux, William G. Benson, Andrew J. Young, Lihong Chen · 2015 · Journal of Pharmacology and Experimental Therapeutics
148. Involvement of the Niacin Receptor GPR109a in the LocalControl of Glucose Uptake in Small Intestine of Type 2Diabetic Mice
     Tung Po Wong, Leo K. Y. Chan, Po Sing Leung · 2015 · Nutrients
149. Sustained improvement in glucose homeostasis in lean and obese mice following chronic administration of the β3 agonist SR 58611A
     Celia A. Williams, Mei‐Fen Shih, Peter V. Taberner · 1999 · British Journal of Pharmacology
150. Enhanced voluntary wheel running in GPRC6A receptor knockout mice
     Christoffer Clemmensen, Christian K. Pehmøller, Anders Bue Klein, Cecilia Ratner, Jørgen F. P. Wojtaszewski, Hans Bräuner‐Osborne · 2013 · Physiology & Behavior
151. The EP3 Receptor: Exploring a New Target for Type 2 Diabetes Therapeutics.
     Joshua Charles Neuman, Michelle E. Kimple · 2013 · PubMed
152. Relationship between Changes in Plasma Adiponectin Concentration and Insulin Sensitivity after Niacin Therapy
     Gemma Fraterrigo, Elisa Fabbrini, Bettina Mittendorfer, Stephen O’Rahilly, Philipp E. Scherer, Bruce W. Patterson, Samuel Klein · 2012 · Cardiorenal Medicine
153. Synthesis and characterization of ester‐based prodrugs of glucagon‐like peptide 1
     Arnab De, Richard D. DiMarchi · 2010 · Biopolymers
154. Discovery and Optimization of a Novel Triazole Series of GPR142 Agonists for the Treatment of Type 2 Diabetes
     Liangqin Guo, Dann L. Parker, Yi Zang, Ramzi Farah Sweis, Weiguo Liu, Edward C. Sherer, Nicole Buist, Jenna L. Terebetski, Terri M. Kelly, Randal M. Bugianesi et al. · 2016 · ACS Medicinal Chemistry Letters
155. Anti Diabetic effect of CL 316,243 (A β3-Adrenergic Agonist) by Down Regulation of Tumour Necrosis Factor (TNF-α) Expression
     Masoud Ghorbani, Mehdi Shafiee Ardestani, Hatami-Gigloo Sedigheh, Reza Ahangari Cohan, Davoud Nouri Inanlou, Peyman Ghorbani · 2012 · PLoS ONE
156. Discovery and pharmacological effects of a novel GPR142 antagonist
     Michiko Murakoshi, Harumi Kuwabara, Miyuki Nagasaki · 2016 · Journal of Receptors and Signal Transduction
157. The molecular biology of mammalian glucose transporters
     Mike M. Mueckler · 1992 · Current Opinion in Nephrology & Hypertension
158. The alpha-1A adrenergic receptor agonist A61603 reduces cardiac polyunsaturated fatty acid and endocannabinoid metabolites associated with inflammation in vivo
     Monte S. Willis, Amro Ilaiwy, Megan D. Montgomery, Paul C. Simpson, Brian C. Jensen · 2016 · Metabolomics
159. GPR21 KO mice demonstrate no resistance to high fat diet induced obesity or improved glucose tolerance
     Jinghong Wang, Zheng Pan, Hélène Baribault · 2016 · F1000Research
160. Design of Potent and Orally Active GPR119 Agonists for the Treatment of Type II Diabetes
     Ping Liu, Zhiyong Hu, Byron G. DuBois et al. · 2015 · ACS Medicinal Chemistry Letters
161. GPR21 KO mice demonstrate no resistance to high fat diet induced obesity or improved glucose tolerance
     Jinghong Wang, Zheng Pan, Hélène Baribault · 2016 · F1000Research
162. Identification of the first surrogate agonists for the G protein-coupled receptor GPR132
     Mohamed A. Shehata, Hanna Belcik Christensen, Vignir Ísberg, Daniel Sejer Pedersen, Andreas Bender, Hans Bräuner‐Osborne, David E.I. Gloriam · 2015 · RSC Advances
163. Prostaglandin EP3 Receptor Antagonists May Provide Novel Treatment for Diabetes
     Ahmed F. Abdel‐Magid · 2015 · ACS Medicinal Chemistry Letters
164. The Succinate Receptor 1 is a Physiological Regulator of the Renin‐Angiontensin Aldosterone System
     Claudia Carmone, Joris Robben, Ana Carolina Ariza · 2015 · The FASEB Journal
165. The Succinate Receptor Contributes to Obesity‐Induced Diabetes Type‐II and Chronic Kidney Disease
     Claudia Carmone, Joris Robben, Janna A. van Diepen · 2015 · The FASEB Journal